Advertisement
NEO vs NTRA
Which Stock Would AI Choose? NeoGenomics (NEO) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Both NEO and NTRA are precision-diagnostics companies, but they occupy very different positions: NeoGenomics is a smaller, community-oncology-focused testing lab, while Natera is a much larger cell-free DNA (cfDNA) leader spanning oncology, women's health, and organ health.
- Momentum favors scale: Natera has grown quarterly revenue roughly 38–40% year over year, versus NeoGenomics' low-double-digit growth, and carries a market capitalization many times larger.
- Valuation presents a trade-off: NeoGenomics trades at a lower price-to-sales multiple and is earlier in its profitability turnaround, while Natera commands a premium multiple reflecting faster, more established growth.
- Tickeron AI Verdict: Based on observable trend consistency, growth momentum, and market positioning, Tickeron's AI currently favors NTRA as the stronger relative candidate between the two.
- For additional context on each name, explore NEO Major News, NEO Today's Price Move, NTRA Major News, and NTRA Today's Price Move.
- To see which automated strategies are currently leading the market, explore Trending AI Robots.
Introduction
This stock comparison examines two publicly traded companies operating in the fast-growing field of genomic and molecular diagnostics: NeoGenomics and Natera. Both are central to the shift toward precision medicine, yet their business models, scale, and growth trajectories differ meaningfully. For investors and traders evaluating the oncology-testing and liquid-biopsy opportunity, understanding these contrasts in relative performance and market positioning can help clarify which profile aligns with a given strategy. The comparison is particularly relevant for those weighing a high-growth, market-leading diagnostics franchise against a smaller, turnaround-oriented specialist trading at a more modest valuation.
NEO Overview and Recent Performance
NeoGenomics is a pure-play precision oncology company serving the community oncology channel, where an estimated 80% of cancer patients receive treatment. Its testing portfolio spans next-generation sequencing (NGS, a technique for rapidly reading DNA and RNA), hematology, and a growing molecular residual disease (MRD) offering. In recent weeks, the company reported third-quarter results that beat expectations, with revenue up roughly 11% year over year and NGS revenue climbing around 29%. Management raised full-year guidance, and the company also announced a leadership transition, with President and COO Warren Stone set to become CEO.
Recent market activity has been strong but uneven. The stock has delivered a substantial year-to-date advance, yet a short-term pullback followed the leadership-change announcement as investors digested the succession plan. Sentiment has been supported by analyst upgrades, reimbursement progress for its RaDaR ST MRD test, and continued margin improvement, while remaining tempered by a legacy pharma services segment that continues to face headwinds.
NTRA Overview and Recent Performance
Natera is a global leader in cell-free DNA testing, operating across three core businesses: oncology, women's health, and organ health. Its flagship product, Signatera, is a widely adopted tumor-informed MRD test used by more than half of U.S. oncologists. In recent quarters, Natera reported revenue growth near 38–40% year over year, driven by record testing volumes and rising average selling prices, and it raised its full-year outlook. Recent catalysts include FDA (Food and Drug Administration) regulatory milestones, expanded reimbursement, and a growing body of clinical data presented at major medical congresses.
The stock has delivered a substantial year-to-date gain and has traded near its 52-week high, reflecting sustained investor enthusiasm. Analysts broadly rate the shares favorably, though the valuation sits near or above many price targets. Momentum is strong, but the shares are also notably volatile, with several moves greater than 5% over the past year, reflecting sensitivity to clinical and reimbursement news.
Trending AI Robots
For traders seeking a systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of its automated trading strategies. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions are featured in this section. Each bot differs in trading style, strategy, timeframe, performance statistics, and the set of tickers it trades, giving users a way to explore automated approaches aligned with their own objectives. Explore Trending AI Robots to see which strategies are currently performing most consistently.
Head-to-Head Comparison
The clearest contrast between NEO and NTRA is scale and growth. Natera generates roughly three to four times NeoGenomics' quarterly revenue and is growing several times faster, with a broader, more diversified testing franchise. NeoGenomics, by contrast, is a more concentrated oncology play that is still building its MRD presence as a "fast follower" to incumbents like Natera.
Risk profiles also differ. NeoGenomics is earlier in its path toward sustained profitability and remains exposed to a declining legacy pharma segment, though its valuation is comparatively modest. Natera carries execution and valuation risk, with a premium multiple that leaves less room for disappointment, despite a stronger record of growth and a market-leading position in MRD testing. In terms of recent momentum and market sentiment, Natera has shown greater consistency, while NeoGenomics offers a potential value-oriented turnaround narrative built on reimbursement wins and margin expansion.
Tickeron AI Verdict
Weighing trend consistency, growth momentum, scale, and relative market positioning, Tickeron's AI currently appears to favor Natera over NeoGenomics. Natera's faster revenue growth, market-leading MRD franchise, and broader product diversification provide a steadier observable trend, while NeoGenomics' smaller scale and earlier-stage profitability turnaround introduce additional uncertainty. That said, this is a probabilistic assessment, not a certainty: NeoGenomics' lower valuation and improving fundamentals could appeal to investors with a different risk tolerance or a value-oriented timeframe.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEO is a Buy and NTRA is a StrongBuy.
Aroon Indicator for NEO shows an upward move is likely
NEO's Aroon Indicator triggered a bullish signal on September 30, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator showed a similar pattern. In 156 of the 189 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NEO as a result. In 70 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for NEO just turned positive on October 27, 2026. Looking at past instances where NEO's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
Following a +7.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in 215 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 55 cases where NEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
NEO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
NEO broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.696) is normal, around the industry mean (65.876). P/E Ratio (-42.282) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Aroon Indicator for NTRA shows an upward move is likely
NTRA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator showed a similar pattern. In 244 of the 286 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 65 cases where NTRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.986) is normal, around the industry mean (65.876). NTRA's P/E Ratio (-280.681) is considerably lower than the industry average of (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NEO | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 8 | |
SMR RATING 1..100 | 92 | 94 | |
PRICE GROWTH RATING 1..100 | 37 | 35 | |
P/E GROWTH RATING 1..100 | 66 | 86 | |
SEASONALITY SCORE 1..100 | 44 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is in the same range as NEO (27) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to NEO’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for NEO (100) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew significantly faster than NEO’s over the last 12 months.
NEO's SMR Rating (92) in the Medical Or Nursing Services industry is in the same range as NTRA (94) in the Biotechnology industry. This means that NEO’s stock grew similarly to NTRA’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as NEO (37) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to NEO’s over the last 12 months.
NEO's P/E Growth Rating (66) in the Medical Or Nursing Services industry is in the same range as NTRA (86) in the Biotechnology industry. This means that NEO’s stock grew similarly to NTRA’s over the last 12 months.
| NEO | NTRA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| Advances ODDS (%) | 7 days ago 78% | 6 days ago 80% |
| Declines ODDS (%) | 2 days ago 81% | 2 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 85% |
| Aroon ODDS (%) | 5 days ago 83% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NEO’s FA Score shows that 1 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- NEO’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NEO’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- NEO’s TA Score: 4 bullish, 5 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
NEO (@Medical Specialties) experienced а -1.20% price change this week, while NTRA (@Medical Specialties) price change was -6.42% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.47%. For the same industry, the average monthly price growth was -4.50%, and the average quarterly price growth was +42.79%.
Reported Earning Dates
NEO is expected to report earnings on Feb 23, 2027.
NTRA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical Specialties (-1.47% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -8.54% | ||
| ADPT - NTRA | 55% Loosely correlated | -5.93% | ||
| NEO - NTRA | 55% Loosely correlated | -5.12% | ||
| GH - NTRA | 54% Loosely correlated | -4.51% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.12% | ||
| TMO - NTRA | 48% Loosely correlated | -2.06% | ||
More | ||||